Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2026)

Kiniksa Pharmaceuticals International has reported Other Non Operating Income for 5 years, with the latest figure at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 48.89% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 34.53% YoY), and the FY2025 full-year result was $11.6 million, up 23.07% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $3.4 million, down from $3.5 million in the prior quarter.
• The five-year high for Other Non Operating Income was $3.5 million in Q4 2025, with the low at $34000.0 in Q1 2022.
• Historically, Other Non Operating Income has averaged $2.0 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 5288.24% — and 2024, when it retreated 2.07%.
• Kiniksa Pharmaceuticals International's Other Non Operating Income stood at $794000.0 in 2022, then surged by 198.36% to $2.4 million in 2023, then fell by 2.07% to $2.3 million in 2024, then jumped by 50.91% to $3.5 million in 2025, then fell by 2.49% to $3.4 million in 2026.
• The last three Other Non Operating Income figures came in at $3.4 million (Q1 2026), $3.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.